Lisa Swanson, MD, FAAD

On this episode of Don't Be Rash, Lisa Swanson, MD, joined host Andrew C. Krakowski, MD, to walk through the pediatric psoriasis treatment ladder, from first-line topicals to biologics and a new oral IL-23 blocker.

Lisa Swanson, MD, joins Don't Be Rash host Andrew C. Krakowski, MD, for Psoriasis Awareness Month to discuss how pediatric psoriasis is often misdiagnosed and when it signals a heightened risk of psoriatic arthritis in kids.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Lisa Swanson, MD, discussed strategies for counseling patients on JAK inhibitor safety and where she sees the drug class expanding next in a recent Dermatology Times interview.

At Elevate Derm, Lisa Swanson, MD, discussed earlier oral JAK inhibitor use for alopecia areata and selecting appropriate patients.

At Winter Clinical Miami, Lisa Swanson, MD, FAAD, shared practical, prior authorization–free treatment strategies while calling for expanded therapeutic options and earlier research inclusion for children under 12.

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.

At MOPD 2026, Lisa Swanson, MD, urges fungal cultures amid terbinafine resistance and warns attendees about risky kids’ skin care trends.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.

Lisa Swanson, MD, FAAD, shares innovative insights on pediatric dermatology, emphasizing effective treatments and communication strategies for young patients at DERM 2025.

Swanson discussed new and upcoming therapeutics, and how she approaches treatment options with caregivers.

Lisa Swanson, MD, discusses the unmet needs in pediatric dermatology at the DERM 2025 conference.

At RAD 2025, pediatric dermatologist Lisa Swanson, MD, and allergist Anne Marie Singh, MD, led a dual session aimed at demystifying the connection between food allergy and atopic dermatitis.

Panelists discuss how data from head-to-head clinical trials comparing different therapeutic options in atopic dermatitis inform treatment decisions while exploring critical gaps in research that future studies need to address.

Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.

Panelists discuss how individual patient characteristics, including comorbidities, treatment history, and personal preferences, guide therapeutic decision-making for a 38-year-old woman with severe atopic dermatitis.

Panelists discuss how to optimize treatment outcomes by managing the transition from biologics to JAK inhibitors and considering dose adjustment strategies when patients show inadequate response to initial therapy.

Panelists discuss how clinicians can recognize and address barriers to treatment advancement in a young adult with persistent moderate to severe atopic dermatitis by evaluating disease impact, patient concerns, and appropriate therapeutic options.

Lisa Swanson, MD, FAAD, discusses how to balance the need for effective control of Alzheimer's disease symptoms with concerns about long-term safety, particularly when introducing new therapies.

Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.

Lisa Swanson, MD, FAAD, discusses how caregivers play a crucial role in ensuring successful long-term AD management by providing daily support, monitoring treatment adherence, and offering emotional support, while dermatologists can better support them through education, clear communication, and collaborative care strategies.

Lisa Swanson, MD, FAAD, discusses how current treatment options for this age group fall short in terms of disease control, safety, and ease of use, while highlighting emerging options that promise better efficacy, fewer side effects, and greater convenience.

Lisa Swanson, MD, FAAD, discusses how pediatric atopic dermatitis (AD) treatment challenges include limited approved options, safety concerns, and adherence issues. Effective management requires balancing new therapies like Janus kinase (JAK) inhibitors with safety while supporting caregivers through education.

Panelists discuss how unique characteristics of different JAK inhibitors, including selectivity profiles, administration routes, and clinical efficacy data, inform treatment selection in real-world practice.

Panelists discuss how to implement and maintain appropriate laboratory monitoring protocols when prescribing oral JAK inhibitors, ensuring patient safety through regular assessment of key clinical parameters.

Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.

Panelists discuss how clinicians can interpret and apply the JAK inhibitor class boxed warning to make informed treatment decisions while weighing potential risks against therapeutic benefits for individual patients.

Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.

Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.